|Day Low/High||41.61 / 43.76|
|52 Wk Low/High||29.88 / 127.20|
A break in a key support level could precipitate further declines in the life sciences company's shares.
A correction in EBS could soon set up an attractive opportunity.
This Friday several banks begin the unofficial kickoff of 'earnings season'.
The sooner that we get jabbed the more likely the economy can spring back to life.
Most of the indicators are still bullish in this name, although some profit-taking may be occurring.
Instead of scratching your head and saying the market defies logic, look to the Cramer Covid-19 Index.
Let's check the charts and come up with a trading strategy.
Let's check out the latest charts and indicators.
EBS has been in an uptrend for a long time.
Investors may consider dosing up on the long side of this vaccine provider.
EBS stock is poised to make a tradable rally in the weeks ahead.
Seven experts select their best ideas among aerospace and naval contractors, drones, building security, biological threats and cybersecurity.
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
These lesser-known diagnostic and life sciences firms are involved in areas from genetic tools to telemedicine.
Try and remember that life isn't about Jan. 1 through Dec. 31, so why should your returns be?
Portfolio manager David Peltier finds a pharmaceutical name that is quietly growing faster than its peers.
Let's see how the manufacturing data stack up over the next 24 hours. On the corporate profit front, earnings continue to be disappointing. Over there, in Europe, UBS (UBS), BP (BP) and Anheuser-Busch InBev (BUD) missed, and their share prices are d...